Table 5.

Summary of selected meta-analyses on indirect comparison between immunotherapies in stage IV NSCLC.

References	Objective(s)	N studies	N pts	Main results
Wang et al. (63)	Comparative efficacy of 1st line ICI in wild-type NSCLC (nivolumab, atezolizumab, pembrolizumab)	9 (RCT)	5,504	Survival better with pembrolizumab plus chemotherapy than with pembrolizumab alone and other chemo-immunotherapy regimens
Frederickson et al. (64)	Comparative efficacy of 1st line ICI in wild-type non-squamous NSCLC (pembrolizumab, atezolizumab, standard CT)	22 (RCT)	11,178	Pembrolizumab-platinum doublet has 95.6% probability to be the best treatment for OS Pembrolizumab-platinum doublet has 67.3% probability to be the best treatment for PFS
Passiglia et al. (65)	Comparative efficacy of 2nd line ICI (nivolumab, atezolizumab, pembrolizumab)	5 (RCT)	3,355	ORR: nivolumab = pembrolizumab, nivolumab > atezolizumab, pembrolizumab > atezolizumab PFS: nivolumab = pembrolizumab = atezolizumab OS: nivolumab = pembrolizumab = atezolizumab AE: nivolumab better than pembrolizumab and atezolizumab, pembrolizumab = atezolizumab

ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; CT, chemotherapy; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; AE, adverse events.